FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	es)														
Name and Address of Reporting Person * Kang Y Michele				2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RXHN]							n	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O REXAHN PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 06/11/2007							Officer (give title below) Other (specify below)					
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ Fo:	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
ROCKVILLE, MD 20850 (City) (State) (Zip)				Table I - Non-Derivative Securities Acqui												
1.Title of S (Instr. 3)	Title of Security nstr. 3) 2. Transaction Date (Month/Day/Yea		2A. Deemed Execution Da any (Month/Day/		ed Date, if	3. Tı Code (Inst	ransaction 4 e (r. 8) (on 4. Securities Acqu (A) or Disposed o (Instr. 3, 4 and 5) (A) or		red 5. Am Owned Transa	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		neficially	5. 7. Ownership of	eneficial wnership	
Reminder:	Report on a	separate line for eac						Persor in this	s wh form	no respond are not rec currently va	quired to r alid OMB o	espond control n	unless the		ned SEC 14	74 (9-02)
				(e.g., pu	ts, c			ts, options, co								
Security	Conversion	3. Transaction Date (Month/Day/Year)	Execution Date, if	Code				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$ 1.2							05/01/2007	7(1)	05/01/2016	Common Stock	20,000		20,000	D	
Stock Option (Right to Buy)	\$ 1.4	06/11/2007		A		20,000		06/11/2008	3 <mark>(1)</mark> (06/11/2017	Common Stock	20,000	\$ 0	20,000	D	

Reporting Owners

Donostino Ossar Norma / Addisor	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Kang Y Michele C/O REXAHN PHARMACEUTICALS, INC. 9620 MEDICAL CENTER DRIVE ROCKVILLE, MD 20850	X						

Signatures

/s/ Tae Heum Jeong, as attorney-in-fact for Y. Michele Kang	06/13/2007
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options fully vest on the first anniversary of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.